Newsfeeds
Breaking World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements.

World Pharma News
  • Mutations prevent programmed cell death
    Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Now, researchers at Technische Universität München (TUM) have discovered a previously unknown mechanism for regulating programmed cell death.

  • New European consortium formed to help further advance development of a GSK/NIH Ebola candidate vaccine
    GlaxoSmithKlineA new European consortium has been formed including GSK and three leading research institutions to help further advance development of a candidate vaccine against Ebola, which is being co-developed by GSK and the US National Institutes of Health (NIH).

  • Low glycemic diet does not improve risk factors for cardiovascular disease and diabetes
    Nutrition experts are continually debating the nutritional value of carbohydrate-containing foods and whether some are healthier than others. High carbohydrate foods are classified by how much they increase blood sugar; known as glycemic index. In new findings led by researchers at Brigham and Women's Hospital (BWH) in Boston and Johns Hopkins University (JHU) in Baltimore, researchers looked at

  • New targeted drugs could treat drug-resistant skin cancer
    A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports. Clinical trials to test the new drugs in patients should begin as early as 2015. Existing drugs target faulty versions of a protein called BRAF which drives about half of all melanomas, but while initially very effective, the cancers almost always become resistant to treatment within a year.

  • Injectable 3D vaccines could fight cancer and infectious diseases
    One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard's School of Engineering and Applied Sciences (SEAS) show a non-surgical injection of programmable biomaterial that spontaneously assembles in vivo into a 3D structure could fight and even help prevent cancer and also infectious disease such as HIV.

  • Abbott completes acquisition of Veropharm
    AbbottAbbott (NYSE: ABT) today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has had a presence in Russia for nearly 40 years and, in line with its long-term commitment to growing global healthcare markets and capabilities, the company is committed to providing a reliable supply of its healthcare products to Russian patients.

  • Can researchers develop 100 drugs in 10 years?
    Develop 100 drugs in 10 years. That's the ambitious goal set by a group of scientists and engineers at the University of Utah, founders of Recursion Pharmaceuticals, a start-up company that is able to quickly and affordably identify unexpected ways a drug could be used by testing it on diseased cells.

  • Study shows new kind of targeted drug has promise for leukemia patients
    A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented at the 56th Annual Meeting of the American Society of Hematology.

  • Top-selling eye vitamins found not to match scientific evidence
    With Americans spending billions of dollars each year on nutritional supplements, researchers have analyzed popular eye vitamins to determine whether their formulations and claims are consistent with scientific findings. They determined that some of the top-selling products do not contain identical ingredient dosages to eye vitamin formulas proven effective in clinical trials.

  • Pfizer expands rare disease research with establishment of gene therapy platform
    PfizerPfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company's rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.